TBXA2R

Across TCGA pan-cancer cohorts, TBXA2R Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TBXA2R data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher TBXA2R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBXA2R expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, SCLC, and PRAD are the cancer types where TBXA2R Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SCLC	OS	Median	III,IV	0.082	0.639	<.001	12	view →
PRAD	DFS	Median	All	0.592	0.936	<.001	12	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.188	0.676	.027	4	view →
SKCM	DFS	Median	II,III,IV	0.872	0.545	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TBXA2R–THYM (OS)

Open the THYM breakdown →